ABBOTT LABORATORIES — Director's Dealing 2023

Feb 23, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2023-02-17

Reporting Person: Tyler Julie L. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-17	Common shares without par value	A	7920	—	Acquired	41788	Direct
2023-02-19	Common shares without par value	F	291	$106.74	Disposed	41497	Direct
2023-02-21	Common shares without par value	F	341	$106.74	Disposed	41156	Direct
2023-02-22	Common shares without par value	S	260	$103.24	Disposed	40896	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-17	Option (right to buy)	$106.24	A	31236	Acquired	2033-02-16	Common Shares (31236)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	9513	Indirect

Footnotes

F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

F2: Balance in the Abbott Laboratories Stock Retirement Trust as of February 17, 2023.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,412 on February 17, 2024, 10,412 on February 17, 2025 and 10,412 on February 17, 2026.